Panel firm offers speedy trend analysis

Share this article:
All Global, a Kantar-owned provider of healthcare panel data, has launched a service designed to offer, within 24 hours, analyzed responses to breaking drug news.
The service, Snapshot, can generate sample sizes in the hundreds across six countries, according to a release. For example, within hours of the FDA's decision to severely restrict use of GlaxoSmithKline diabetes pill Avandia, Snapshot closed a survey of 100 UK diabetes specialists and endocrinologists, with 63% saying the news would encourage their use of a DPP 4 inhibitor/GLP 1 mimetic, 12% saying they would initiate insulin earlier, and 13% saying they would not change Rx habits.
Release of FDA ad-com briefing documents for weight-loss candidate Qnexa prompted a Snapshot survey of 730 US PCPs, with 82% saying they would recommend approval. In a follow-up survey of 398 PCPs after the ad-com voted 10-6 against approval, 68% said they would have recommended approval.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"